George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors
Longeveron (NASDAQ: LGVN), a clinical stage biotechnology company, has appointed Dr. George Paletta, Jr. to its Board of Directors. Dr. Paletta brings extensive experience as an orthopedic surgeon, entrepreneur, and investor, having participated in ASC deals totaling nearly $1 billion.
Dr. Paletta joins Longeveron at a crucial time as the company advances its stem cell therapy pipeline, including a fully enrolled pivotal clinical trial in HLHS with data expected in 2026. The company focuses on developing cellular therapies for life-threatening rare pediatric and chronic aging-related conditions.
As the St. Louis Cardinals' head team doctor, Dr. Paletta holds multiple patents in orthopedic and cardiovascular fields and has founded Preston Worldwide, a medical device company. He completed his medical education at Johns Hopkins and holds an MBA from Washington University's Olin School of Business.
Longeveron (NASDAQ: LGVN), una società biotecnologica in fase clinica, ha nominato il Dott. George Paletta, Jr. al suo Consiglio di Amministrazione. Il Dott. Paletta porta una vasta esperienza come ortopedico, imprenditore e investitore, avendo partecipato ad accordi ASC per quasi un miliardo di dollari.
Il Dott. Paletta entra in Longeveron in un momento cruciale mentre l’azienda avanza nel suo portafoglio di terapie a base di cellule staminali, tra cui uno trial clinico fondamentale completamente reclutato per HLHS con dati attesi nel 2026. L’azienda si concentra sullo sviluppo di terapie cellulari per condizioni pediatriche rare potenzialmente letali e per condizioni legate all’invecchiamento cronico.
In qualità di medico capo della squadra degli St. Louis Cardinals, il Dott. Paletta detiene numerosi brevetti nei campi ortopedico e cardiovascolare e ha fondato Preston Worldwide, una società di dispositivi medici. Ha completato la sua formazione medica a Johns Hopkins e possiede un MBA presso la Olin School of Business della Washington University.
Longeveron (NASDAQ: LGVN), una empresa de biotecnología en fase clínica, ha designado al Dr. George Paletta, Jr. para su Junta Directiva. El Dr. Paletta aporta amplia experiencia como cirujano ortopédico, emprendedor e inversionista, habiendo participado en acuerdos ASC por casi mil millones de dólares.
El Dr. Paletta se une a Longeveron en un momento crucial mientras la compañía avanza en su pipeline de terapias con células madre, incluyendo un ensayo clínico pivotal totalmente inscrito en HLHS con datos esperados para 2026. La empresa se centra en desarrollar terapias celulares para condiciones pediátricas raras y potencialmente mortales y para asuntos relacionados con el envejecimiento crónico.
Como médico jefe del equipo de los St. Louis Cardinals, el Dr. Paletta posee múltiples patentes en los campos ortopédico y cardiovascular y ha fundado Preston Worldwide, una empresa de dispositivos médicos. Completó su educación médica en Johns Hopkins y posee un MBA de la Olin School of Business de la Washington University.
Longeveron (NASDAQ: LGVN)은 임상 단계의 생명공학 기업으로서 Dr. George Paletta, Jr.를 이사회에 임명했습니다. Paletta 박사는 정형외과 의사로서의 광범위한 경력과 기업가, 투자자 경력을 통해 ASC 거래에 약 10억 달러에 달하는 참여를 했습니다.
Paletta 박사는 세포 치료 파이프라인을 추진 중인 이 회사에 중요한 시점에 합류하며, HLHS에서 완전히 등록된 결정적 임상시험을 포함하고 2026년 데이터를 기대하고 있습니다. 이 회사는 생명을 위협하는 희귀 소아 질환 및 만성 노화 관련 질환에 대한 세포 치료 개발에 집중하고 있습니다.
세인트루이스 카디널스의 주치의로서 Paletta 박사는 정형외과 및 심혈관 분야에서 다수의 특허를 보유하고 있으며 Preston Worldwide라는 의료기기 회사를 설립했습니다. 그는 Johns Hopkins에서 의학 교육을 마쳤고 Washington University의 Olin School of Business에서 MBA를 취득했습니다.
Longeveron (NASDAQ: LGVN), une société biotechnologique en phase clinique, a nommé le Dr George Paletta, Jr. à son conseil d’administration. Le Dr Paletta apporte une vaste expérience en tant que chirurgien orthopédique, entrepreneur et investisseur, ayant participé à des accords ASC pour près de un milliard de dollars.
Le Dr Paletta rejoint Longeveron à un moment crucial alors que l’entreprise fait progresser son portefeuille de thérapies par cellules souches, comprenant un essai clinique pivot entièrement recruté pour la HLHS dont les données sont attendues en 2026. L’entreprise se concentre sur le développement de thérapies cellulaires pour des affections pédiatriques rares potentiellement mortelles et des conditions liées au vieillissement chronique.
En tant que médecin-chef de l’équipe des St. Louis Cardinals, le Dr Paletta détient de nombreux brevets dans les domaines orthopédiques et cardiovasculaires et a fondé Preston Worldwide, une entreprise de dispositifs médicaux. Il a effectué ses études médicales à Johns Hopkins et possède un MBA de la Olin School of Business de l’Université Washington.
Longeveron (NASDAQ: LGVN), ein biotechnologisches Unternehmen in klinischer Phase, hat Dr. George Paletta, Jr. in den Vorstand berufen. Dr. Paletta bringt umfassende Erfahrung als Orthopäde, Unternehmer und Investor mit und war an ASC-Deals beteiligt, die sich auf nahezu eine Milliarde Dollar belaufen.
Dr. Paletta tritt Longeveron in einer entscheidenden Phase bei, da das Unternehmen seine Stammzelltherapie-Pipeline vorantreibt, darunter eine vollständig eingeschriebene zentrale klinische Studie in HLHS mit Daten, die 2026 erwartet werden. Das Unternehmen konzentriert sich auf die Entwicklung zellulärer Therapien für lebensbedrohliche seltene pädiatrische Bedingungen und chronische altersbedingte Erkrankungen.
Als Chefarzt der St. Louis Cardinals hat Dr. Paletta mehrere Patente in den Bereichen Orthopädie und Herz-Kreislauf und gründete Preston Worldwide, ein Unternehmen für medizinische Geräte. Er absolvierte seine medizinische Ausbildung an der Johns Hopkins University und besitzt einen MBA von der Olin School of Business der Washington University.
Longeveron (NASDAQ: LGVN)، شركة تكنولوجيـا حيوية في مرحـلة سريرية، عينت الدكتور جورج باليتا الابن في مجلس إدارتها. يجلب الدكتور باليتا خبرة واسعة كجراح عظام ورجل أعمال ومُستثمر، شارك في صفقات ASC بإجمالي يقارب مليار دولار.
ينضم الدكتور باليتا إلى لوجينيفون في وقت حاسم بينما تتقدم الشركة في خطوط أنابيب علاجات الخلايا الجذعية، بما في ذلك تجربة سريرية محورية مكتملة التسجيل في HLHS مع توقع بيانات في عام 2026. تركيز الشركة على تطوير علاجات خلوية لظروف نادرة عند الأطفال وخطيرة مهددة للحياة ولظروف مرتبطة بالشيخوخة المزمنة.
بوصفه الطبيب الرئيسي لفريق سانت لويس كاردينالس، يمتلك الدكتور باليتا العديد من براءات الاختراع في مجالي العظام والقلب والأوعية الدموية وأسّس Preston Worldwide، وهي شركة معدات طبية. أكمل دراسته الطبية في Johns Hopkins ويحمل MBA من كلية Olin للعلوم التجارية بجامعة واشنطن.
Longeveron (NASDAQ: LGVN)，一家处于临床阶段的生物技术公司，任命了George Paletta, Jr.博士加入董事会。Paletta博士拥有丰富的正畸外科医生、企业家和投资者经验，参与的ASC交易总额近10亿美元。
Paletta博士在公司推进干细胞治疗管线的关键时刻加入，其中包括一个HLHS完全入组的关键性临床试验，预计2026年有数据。公司专注于开发用于威胁生命的罕见儿科疾病和与慢性衰老相关状况的细胞治疗。
作为圣路易斯红雀队的首席队医，Paletta博士在正畸和心血管领域拥有多项专利，并创办了 Preston Worldwide，一家医疗设备公司。他在约翰斯·霍普金斯大学完成医学教育，并在华盛顿大学奥林商学院获得工商管理硕士学位。
- Strategic addition of Dr. Paletta brings significant medical device and entrepreneurial experience with billion-dollar deal expertise
- Fully enrolled pivotal clinical trial in HLHS with data expected in 2026 shows pipeline progress
- Board strengthened with expertise spanning medical practice, business development, and investment
- Company still in clinical stage without commercialized products
MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that George Paletta, Jr., MD, MBA, has been elected to the Longeveron Board of Directors. Dr. Paletta is a nationally and internationally recognized orthopedic surgeon and the head team doctor for the St. Louis Cardinals. Dr. Paletta is a developer of ambulatory surgical centers (ASCs), and has participated in the selling of two ASCs with deal values totaling almost
“I am delighted to welcome George, and his tremendous experience as a physician, inventor, entrepreneur, and investor, to the Board of Directors,” said Joshua Hare, Co-founder, Chief Science Officer and Executive Chairman of the Board at Longeveron. “His broad experience across multiple business areas will bring significant value to Longeveron as we continue to advance our stem cell therapies addressing life threatening conditions in the most vulnerable populations - children and the elderly. With our expanding stem cell therapy pipeline, including our fully enrolled pivotal clinical trial in HLHS with data anticipated in 2026, this is an incredibly exciting period for Longeveron, our patients and our shareholders. I look forward to collaborating with George to advance these important stem cell programs.”
“I am excited to join the Longeveron Board at this transformational period for the Company,” said Dr. Paletta. “Both stem cell research and Longeveron have come a long way since the Company’s founding. As a physician, I see tremendous potential for stem cell therapy to bring new treatment options to patients suffering from rare pediatric and chronic aging-related conditions. As an entrepreneur, I see incredible opportunity for Longeveron to be a leader in commercializing stem cell therapies, for the benefit of healthcare in general, patients and shareholders.”
Dr. Paletta holds multiple patents, in both orthopedic and cardiovascular arenas. He led the founding and development of Preston Worldwide, a medical device company built around the sling and pillow technology. He has been a frequent early phase investor in multiple start-up ventures across a wide range of industries and technologies, serving in both formal and informal advisory roles.
Dr. Paletta received his Bachelor of Arts in Chemistry from the College of Holy Cross and his Doctor of Medicine from the Johns Hopkins University School of Medicine. His orthopedic residency was completed at the world-renowned Hospital for Special Surgery in New York City. His training included 3 post-graduate fellowships at Hospital for Special Surgery, The Cleveland Clinic and Children’s Hospital of Michigan. His professional career has included both academic and private practice at Hospital for Special Surgery, Washington University School of Medicine Department of Orthopedic Surgery and, most recently, The Orthopedic Center of St. Louis. He completed his MBA from the Olin School of Business at Washington University in St Louis.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, Pediatric Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/f106bde7-972a-4687-a91e-03e924f409fc
https://www.globenewswire.com/NewsRoom/AttachmentNg/f7ff89b8-dd7e-4951-abb2-68715a4e3e67
FAQ
Who is Dr. George Paletta Jr. and why did LGVN appoint him to their Board?
What are Longeveron's (LGVN) main focus areas for stem cell therapy?
When will Longeveron (LGVN) release data from its HLHS clinical trial?
What is Dr. Paletta's background and expertise?
How does Dr. Paletta's appointment benefit LGVN shareholders?
